Deutsch
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
Journal of Neurological Surgery, Part A: Central European Neurosurgery 2014-Jul

Epilepsy, headache, and quality of life after resection of cerebral arteriovenous malformations.

Nur registrierte Benutzer können Artikel übersetzen
Einloggen Anmelden
Der Link wird in der Zwischenablage gespeichert
Benjamin Rohn
Daniel Haenggi
Nima Etminan
Mathias Kunz
Bernd Turowski
Hans-Jakob Steiger

Schlüsselwörter

Abstrakt

BACKGROUND

In ruptured and unruptured arteriovenous malformations (AVMs), bleeding and re-bleeding rate and efficacy of microsurgical, endovascular, and radiosurgical treatment to prevent hemorrhage are well known. Uncertainty exists concerning the benefit of therapy with regard to headache, epilepsy, and quality of life (QoL) in unruptured AVMs. The objective of the present study was to gain long-term follow-up information after microsurgical AVM resection, in particular with regard to epilepsy, headache, and QoL.

METHODS

A series of 110 patients with cerebral AVM, surgically treated between 1994 and 2009, were analyzed. Epidemiological, sociodemographic, and disease-related characteristics were extracted from the patient records. A detailed follow-up interview was possible with 51 patients after a median of 7 ± 5 years after surgery. A structured telephone interview using the Short Form (SF)-36 for QoL assessment was performed. In addition, specific questions regarding epilepsy and seizure outcome as well as independence and professional activity were asked.

RESULTS

Hemorrhage led to hospital admission in 58.2% patients; 35.5% were admitted with epileptic seizures and 24.5% of patients reported chronic headaches. On the Spetzler-Martin scale, 26.0% were grade 1, 38% grade 2, 25% grade 3, and 11% grade 4. Preoperative embolization was performed in 43.6%. Treatment-associated new neurological deficits at the time of discharge from the hospital occurred in 25.5%. At the time of follow-up, 94.2% of the patients were completely independent (Barthel index of 100). 64.7% of the patients with preoperative epilepsy were free of disabling seizures or rarely have disabling seizures (Engel class 1 and 2), 16.7% reported no significant change, and 17.6% reported worsening. A total of 17.6% patients in whom epilepsy was not known at the time of AVM treatment reported new seizures after therapy, all but one had hemorrhage. 38.5% of patients with preoperative chronic headache reported improvement, 53.8% no change, and 7.7% deterioration. Regarding SF-36 QoL scores, a statistically significant difference from the age-matched German norm values was found in the dimensions Bodily Pain (p = 0.03) and Emotional Role Function (p = 0.04). There was a trend for lower physical and mental sum scores in patients undergoing emergency surgery.

CONCLUSIONS

SF-36-based QoL scores after treatment of AVM differ little from the age-matched German averages. The long-term results regarding chronic epilepsy and chronic headache need further analysis.

Treten Sie unserer
Facebook-Seite bei

Die vollständigste Datenbank für Heilkräuter, die von der Wissenschaft unterstützt wird

  • Arbeitet in 55 Sprachen
  • Von der Wissenschaft unterstützte Kräuterkuren
  • Kräutererkennung durch Bild
  • Interaktive GPS-Karte - Kräuter vor Ort markieren (in Kürze)
  • Lesen Sie wissenschaftliche Veröffentlichungen zu Ihrer Suche
  • Suchen Sie nach Heilkräutern nach ihrer Wirkung
  • Organisieren Sie Ihre Interessen und bleiben Sie über Neuigkeiten, klinische Studien und Patente auf dem Laufenden

Geben Sie ein Symptom oder eine Krankheit ein und lesen Sie über Kräuter, die helfen könnten, geben Sie ein Kraut ein und sehen Sie Krankheiten und Symptome, gegen die es angewendet wird.
* Alle Informationen basieren auf veröffentlichten wissenschaftlichen Forschungsergebnissen

Google Play badgeApp Store badge